Momenta Pharmaceuticals, Inc. (MNTA)

[indigokid]

MNTA 3Q 10Q - is a bit different...and change can be good.

Skimming through the 10Q I am guessing the new CFO started early - maybe a trial period? There seems to be a slight shift in presentation of numbers, but a dramatic shift in discussion attitude.

I anticipated a short read but have spent much longer on it this time. While longer it is much more informative than the usual MNTA 10Q from a perspective of more investor oriented disclosure.

I think MNTA has struggled with disclosure due to scientific secrecy necessary in a highly competitive environment and this has come at the frustration of investors. It seems like they are starting to reach toward a middle ground.

IMO the science has always been top notch now its time to ramp up the finance side so we can get comfortably above $1b and move towards $10B - without dilution please! A near term 40mg approval and a good deal with Humira should move the needle significantly.

MNTA is complex due to: the variety of collaborations, differing product spectrums (heparin, complex amino acids, biologics, and novel drugs - IVIG) FDA, Orange book issues as well as still evolving biologic regulations, and if that weren't enough there are numerous complex litigations involving both IP and interpretations of legislation (h-w). Not to even mention fierce market competitors eg Teva, coupled with insufferably long FDA approvals which has painfully delayed organic self-funding.

Previous 10Q's made required reading of the 10k just to try to get a sense of it all and even then it's been challenging. These issues are now well summarized and well presented for the sophisticated, but not necessarily scientific investor (Wall Street).

I like the change and think other investors will too. I hope it can be articulated as well on the road. MNTA has a good but complex story and needs to be told well. IMO this is a step in the right direction...I'm looking forward to a new voice on the webcasts!